Redeye’s comments on the launch of BLAZE. Free analyses, but requires logging in, so below are just excerpts https://www.redeye.se/research/1186568/faron-pharmaceuticals-first-patient-dosed-in-blaze-trial
”We view the scientific rationale as coherent. Tumor-associated macrophages (TAMs) are increasingly recognized as a key driver of immune evasion and secondary resistance to checkpoint inhibitors, which is precisely the biology that bexmarilimab’s Clever-1 blockade is designed to address. The patient population is also commercially relevant”
”expectations should be kept in check” (because it’s an IIT, non-randomized, initially a small phase 1)
”Faron is now moving into an execution-heavy period. We continue to view the IITs as optionality rather than core valuation drivers, as our investment case remains centered on the outcome of BEXERA.”
”Fair value €0.80”